Pre|CISION® Platform Wins R&D Achievement Award
Avacta Group plc has been awarded the Research and Development Achievement Award at the Pharma Industry Awards UK 2026 for its pre|CISION® Platform, recognizing its pioneering work in targeted oncology drugs. The company has achieved significant R&D milestones over the past year, demonstrating the platform's potential to revolutionize cancer treatment by delivering potent anticancer payloads directly to tumors while sparing healthy tissues. This award highlights the successful advancement of their Next Gen pipeline, including the rapid progression of their first candidate, AVA6103, into clinical trials, with recent data supporting the mechanism's efficacy.
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
| The pre | CISION® Platform Wins Research and Development Achievement Award from Pharma Industry Awards UK 2026 | |
| LONDON and PHILADELPHIA - September 25, 2026 - Avacta Therapeutics (AIM: AVCT, the "Company", "Avacta"), a life sciences company developing innovative, targeted oncology drugs, today announces its pre | CISION® Platform has been honored by the Pharma Industry Awards UK 2026, winning the Research and Development Achievement Award. | |
| The award recognizes that Avacta is pioneering the development of pre | CISION® to transform the landscape of targeted cancer therapies. It cites Avacta's achievement of unprecedented milestones in research and development (R&D) over the last 12 months, demonstrating the platform's potential to transform oncology treatment paradigms. | |
| Christina Coughlin, CEO of Avacta, commented: | ||
| "We are delighted the pre | CISION® platform has received this honor as our scientists and clinicians have worked tirelessly to move the Next Gen pipeline forward and moved the first candidate, AVA6103, into the clinic with record speed. We are thrilled with the recognition of their efforts and the true innovation of the Next Gen pre | CISION® platform, which is designed to deliver highly potent anticancer payloads directly to the tumor, sparing the toxic effects in normal tissues. |
"Our recent clinical data with AVA6103 point to the proof of this mechanism and we look forward to continued updates on the program and our full pipeline. We are grateful to the patients who are participating in the AVA6103 FOCUS-01 trial and for this recognition of our efforts from the Pharma Industry Awards UK 2026."
About AVA6103 (FAP-Exd)
| AVA6103 is the second clinical candidate and is the first asset in the pipeline based on the Next Generation innovative pre | CISION® controlled release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure. AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (F AP-Exd in O ncologic C ancers with U nmet needS). Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload. |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.